MD FACP - Rallybio Corp Chief Officer
| RLYB Stock | USD 1.02 0.03 3.03% |
Insider
MD FACP is Chief Officer of Rallybio Corp
| Age | 73 |
| Address | 234 Church Street, New Haven, CT, United States, 06510 |
| Phone | 203 859 3820 |
| Web | https://www.rallybio.com |
Rallybio Corp Management Efficiency
The company has return on total asset (ROA) of (0.3854) % which means that it has lost $0.3854 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6739) %, meaning that it created substantial loss on money invested by shareholders. Rallybio Corp's management efficiency ratios could be used to measure how well Rallybio Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -0.68. In addition to that, Return On Capital Employed is expected to decline to -0.78. At present, Rallybio Corp's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 204.5 M, whereas Return On Tangible Assets are forecasted to decline to (0.68).Similar Executives
| Showing other executives | INSIDER Age | ||
| MAICD MAICD | Opthea | 48 | |
| Jochen Knolle | Pharvaris BV | 74 | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Jennifer Cormier | PepGen | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Kyle Breidenstine | PepGen | N/A | |
| MD MPH | MediciNova | 56 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Osvaldo Flores | Century Therapeutics | 61 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Gregg Keaney | Third Harmonic Bio | N/A | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Yuichi MD | MediciNova | 74 | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Eric Easom | AN2 Therapeutics | 56 | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.39 |
Rallybio Corp Leadership Team
Elected by the shareholders, the Rallybio Corp's board of directors comprises two types of representatives: Rallybio Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rallybio. The board's role is to monitor Rallybio Corp's management team and ensure that shareholders' interests are well served. Rallybio Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rallybio Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ami Bavishi, Head Communications | ||
| Jonathan MBA, CFO Treasurer | ||
| Martin MacKay, CoFounder Chairman | ||
| MD MB, President, CoFounder | ||
| Jeffrey CPA, CFO CoFounder | ||
| MD FACP, Chief Officer |
Rallybio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rallybio Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (40.35) % | ||||
| Current Valuation | (32.59 M) | ||||
| Shares Outstanding | 41.49 M | ||||
| Shares Owned By Insiders | 4.05 % | ||||
| Shares Owned By Institutions | 76.30 % | ||||
| Number Of Shares Shorted | 463.36 K | ||||
| Price To Book | 0.60 X | ||||
| Price To Sales | 70.76 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Rallybio Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rallybio Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rallybio Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rallybio Corp Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rallybio Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Rallybio Stock refer to our How to Trade Rallybio Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rallybio Corp. If investors know Rallybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rallybio Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.57) | Revenue Per Share 0.014 | Return On Assets (0.39) | Return On Equity (0.67) |
The market value of Rallybio Corp is measured differently than its book value, which is the value of Rallybio that is recorded on the company's balance sheet. Investors also form their own opinion of Rallybio Corp's value that differs from its market value or its book value, called intrinsic value, which is Rallybio Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rallybio Corp's market value can be influenced by many factors that don't directly affect Rallybio Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rallybio Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rallybio Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rallybio Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.